Live Breaking News & Updates on Peter Heerma

Stay updated with breaking news from Peter heerma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Brokerages Set Travere Therapeutics, Inc. (NASDAQ:TVTX) Target Price at $17.85

Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX – Get Free Report) have been assigned an average rating of “Moderate Buy” from the fifteen analysts that are presently covering the company, MarketBeat.com reports. Six equities research analysts have rated the stock with a hold rating and nine have issued a buy rating on the company. The average […] ....

Peter Heerma , Piper Sandler , Christopherr Cline , Zurcher Kantonalbank Zurich Cantonalbank , Wells Fargo Company , Dynamic Technology Lab Private Ltd , Nisa Investment Advisors , Securities Exchange Commission , Travere Therapeutics Company Profile , China Universal Asset Management Co , Travere Therapeutics Inc , Travere Therapeutics , Get Free Report , Exchange Commission , Investment Advisors , Universal Asset Management , Technology Lab Private Ltd , Kantonalbank Zurich Cantonalbank , Get Free , Iga Nephropathy , Travere Therapeutics Daily ,

Travere Therapeutics, Inc. Expected to Earn FY2025 Earnings of ($1.80) Per Share (NASDAQ:TVTX)

Travere Therapeutics, Inc. Expected to Earn FY2025 Earnings of ($1.80) Per Share (NASDAQ:TVTX)
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Christopherr Cline , Piper Sandler , Peter Heerma , Vanguard Group Inc , Jacobs Levy Equity Management Inc , Armistice Capital , Wells Fargo Company , Travere Therapeutics Inc , Travere Therapeutics , Free Report , Travere Therapeutic , Get Free Report , Wells Fargo , Capital Management , Levy Equity Management , Finepoint Capital , Iga Nephropathy , Travere Therapeutics Daily ,

Travere Therapeutics, Inc. (NASDAQ:TVTX) Forecasted to Post FY2028 Earnings of $4.29 Per Share

Travere Therapeutics, Inc. (NASDAQ:TVTX – Free Report) – Equities researchers at HC Wainwright cut their FY2028 earnings estimates for Travere Therapeutics in a report issued on Wednesday, April 24th. HC Wainwright analyst E. Arce now forecasts that the company will earn $4.29 per share for the year, down from their previous estimate of $4.66. HC […] ....

Ericm Dube , Peter Heerma , Piper Sandler , Travere Therapeutics Inc , Wells Fargo Company , Vanguard Group Inc , Healthcare Of Ontario Pension Plan Trust Fund , Travere Therapeutics , Free Report , Travere Therapeutic , Get Free Report , Partners Management , Capital Management , Ontario Pension Plan Trust Fund , Vanguard Group , Iga Nephropathy , Travere Therapeutics Daily , Nasdaq Tvtx , Earnings Estimates , Hc Wainwright ,

HC Wainwright Boosts Travere Therapeutics (NASDAQ:TVTX) Price Target to $19.00

Travere Therapeutics (NASDAQ:TVTX – Get Free Report) had its price target lifted by HC Wainwright from $17.00 to $19.00 in a research report issued to clients and investors on Wednesday, Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s target price indicates a potential upside of 248.62% from the company’s […] ....

United States , Piper Sandler , Peter Heerma , Christopherr Cline , Rice Hall James Associates , Wells Fargo Company , Mirae Asset Global Investments Co , Travere Therapeutics Company Profile , Travere Therapeutics Inc , Securities Exchange Commission , Travere Therapeutics , Get Free Report , Therapeutics Stock Down , Exchange Commission , Retirement System , State Retirement System , Asset Global Investments , Rice Hall James , Hall James , Iga Nephropathy , Travere Therapeutics Daily , Nasdaq Tvtx , Boost Price Target , Hc Wainwright ,